Hepatitis E virus is effectively inactivated in platelet concentrates by ultraviolet C light.
hepatitis E
non-enveloped viruses
pathogen inactivation
platelet concentrates
ultraviolet light
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
02
2020
revised:
28
03
2020
accepted:
15
04
2020
pubmed:
10
5
2020
medline:
3
2
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
As previous investigations have shown, THERAFLEX UV-Platelets, a UVC-based pathogen inactivation (PI) system, is effective against non-enveloped transfusion-relevant viruses such as hepatitis A virus (HAV), which are insensitive to most PI treatments for blood products. This study investigated the PI efficacy of THERAFLEX UV-Platelets against HEV in platelet concentrates (PCs). Buffy coat-derived PCs in additive solution were spiked with cell culture-derived HEV and treated with the THERAFLEX UV-Platelets system using various doses of UVC (0·05, 0·10, 0·15 and 0·20 (standard) J/cm THERAFLEX UV-Platelets dose-dependently inactivated HEV in PCs. The standard UVC dose inactivated the virus to below the limit of detection, corresponding to a mean log reduction of greater than 3·5. Our study demonstrates that the THERAFLEX UV-Platelets system effectively inactivates HEV in PCs.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
As previous investigations have shown, THERAFLEX UV-Platelets, a UVC-based pathogen inactivation (PI) system, is effective against non-enveloped transfusion-relevant viruses such as hepatitis A virus (HAV), which are insensitive to most PI treatments for blood products. This study investigated the PI efficacy of THERAFLEX UV-Platelets against HEV in platelet concentrates (PCs).
MATERIALS AND METHODS
METHODS
Buffy coat-derived PCs in additive solution were spiked with cell culture-derived HEV and treated with the THERAFLEX UV-Platelets system using various doses of UVC (0·05, 0·10, 0·15 and 0·20 (standard) J/cm
RESULTS
RESULTS
THERAFLEX UV-Platelets dose-dependently inactivated HEV in PCs. The standard UVC dose inactivated the virus to below the limit of detection, corresponding to a mean log reduction of greater than 3·5.
CONCLUSION
CONCLUSIONS
Our study demonstrates that the THERAFLEX UV-Platelets system effectively inactivates HEV in PCs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-561Subventions
Organisme : Research Foundation of the German Red Cross Blood Services (Forschungsgemeinschaft der Blutspendedienste des Deutschen Roten Kreuzes)
Organisme : Macopharma S.A.S
Organisme : German Federal Ministry of Health
ID : ZMVI1-2518FSB705
Informations de copyright
© 2020 International Society of Blood Transfusion.
Références
Hewitt PE, Ijaz S, Brailsford SR, et al.: Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014; 384:1766-1773
Matsubayashi K, Kang JH, Sakata H, et al.: A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route. Transfusion 2008; 48:1368-1375
Matsubayashi K, Nagaoka Y, Sakata H, et al.: Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido. Japan. Transfusion 2004; 44:934-940
Tamura A, Shimizu YK, Tanaka T, et al.: Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 2007; 37:113-120
Colson P, Coze C, Gallian P, et al.: Transfusion-associated hepatitis E, France. Emerg Infect Dis 2007; 13:648-649
Haim-Boukobza S, Ferey MP, Vetillard AL, et al.: Transfusion-transmitted hepatitis E in a misleading context of autoimmunity and drug-induced toxicity. J Hepatol 2012; 57:1374-1378
Dreier J, Knabbe C, Vollmer T: Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose. Front Med 2018; 5:5
Riveiro-Barciela M, Sauleda S, Quer J, et al.: Red blood cell transfusion-transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. Transfusion 2017; 57:244-247
Ankcorn MJ, Tedder RS: Hepatitis E: the current state of play. Transfus Med 2017; 27:84-95
Goel A, Vijay HJ, Katiyar H, et al.: Prevalence of hepatitis E viraemia among blood donors: a systematic review. Vox Sang 2020; 115:120-132
Belliere J, Abravanel F, Nogier MB, et al.: Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. Transpl Infect Dis 2017; 19:e12784
Xin S, Xiao L: Clinical manifestations of hepatitis E. Adv Exp Med Biol 2016; 948:175-189
Domanovic D, Tedder R, Blumel J, et al.: Hepatitis E and blood donation safety in selected European countries: a shift to screening? Euro Surveill 2017; 22:1-8
Kamp C, Blumel J, Baylis SA, et al.: Impact of hepatitis E virus testing on the safety of blood components in Germany - results of a simulation study. Vox Sang 2018; 113:811-813
Andonov A, Rock G, Lin L, et al.: Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma. Vox Sang 2014; 107:213-219
Yin X, Li X, Feng Z: Role of envelopment in the HEV life cycle. Viruses 2016; 8:229
Hauser L, Roque-Afonso AM, Beyloune A, et al.: Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014; 123:796-797
Mallet V, Sberro-Soussan R, Roque-Afonso AM, et al.: Transmission of hepatitis E virus with plasma exchange in kidney transplant recipients: a retrospective cohort study. Transplantation 2018; 102:1351-1357
Singh Y, Sawyer LS, Pinkoski LS, et al.: Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46:1168-1177
Owada T, Kaneko M, Matsumoto C, et al.: Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system. Transfusion 2014; 54:2820-2827
Mohr H, Steil L, Gravemann U, et al.: A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009; 49:2612-2624
Seltsam A, Muller TH: UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38:43-54
Douki T, Laporte G, Cadet J: Inter-strand photoproducts are produced in high yield within A-DNA exposed to UVC radiation. Nucleic Acids Res 2003; 31:3134-3142
Faddy HM, Fryk JJ, Prow NA, et al.: Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 2016; 56:1548-1555
Fryk JJ, Marks DC, Hobson-Peters J, et al.: Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light. Transfusion 2017; 57:2677-2682
Castro E, Gonzalez LM, Rubio JM, et al.: The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014; 54:2207-2216
Mohr H, Gravemann U, Bayer A, et al.: Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009; 49:1956-1963
Eickmann M, Gravemann U, Handke W, et al.: Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively. Transfusion 2018; 58:2202-2207
Epstein JS, Vostal JG: FDA approach to evaluation of pathogen reduction technology. Transfusion 2003; 43:1347-1350
World Health Organization: Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products. Geneva: WHO Technical Report 2004; Series No. 924: Annex 4
Gravemann U, Handke W, Lambrecht B, et al.: Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates. Transfusion 2018; 58:2669-2674
Todt D, Friesland M, Moeller N, et al.: Robust hepatitis E virus infection and transcriptional response in human hepatocytes. Proc Natl Acad Sci U S A 2020; 117:1731-1741
Eriksson L, Shanwell A, Gulliksson H, et al.: Platelet concentrates in an additive solution prepared from pooled buffy coats. vivo studies. Vox Sang 1993; 64:133-138
Todt D, Francois C, Anggakusuma, et al.: Antiviral activities of different interferon types and subtypes against hepatitis E virus replication. Antimicrob Agents Chemother 2016; 60:2132-2139
Todt D, Gisa A, Radonic A, et al.: In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut 2016; 65:1733-1743
FaD Administration: Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Fed Reg 1998; 63:51074-51084
Okamoto H: Culture systems for hepatitis E virus. J Gastroenterol 2013; 48:147-158
Fu RM, Decker CC, Dao Thi VL: Cell culture models for hepatitis E virus. Viruses 2019: 11:608
Meister TL, Bruening J, Todt D, et al.: Cell culture systems for the study of hepatitis E virus. Antiviral Res 2019; 163:34-49
McCullough J, Alter HJ, Ness PM: Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion 2019; 59:1132-1146
Wang Y, Zhang H, Ling R, et al.: The complete sequence of hepatitis E virus genotype 4 reveals an alternative strategy for translation of open reading frames 2 and 3. J Gen Virol 2000; 81:1675-1686
Sayed IM, Verhoye L, Cocquerel L, et al.: Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. Gut 2017; 66:920-929
Yin X, Ambardekar C, Lu Y, et al.: Distinct entry mechanisms for nonenveloped and quasi-enveloped hepatitis E viruses. J Virol 2016; 90:4232-4242
Pohler P, Muller M, Winkler C, et al.: Pathogen reduction by ultraviolet C light effectively inactivates human white blood cells in platelet products. Transfusion 2015; 55:337-347
Kim S, Handke W, Gravemann U, et al.: Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates. Transfusion 2018; 58:758-765